Benitec Biopharma (BNTC) AI Stock Analysis

• Market Cap: $342.39M
• Dividend Yield: N/A
• Average Volume (3M): 47.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: -100.00%
• EPS Growth: 72.73%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -2.97
• Shares Outstanding: 25,494,474
• 10 Day Avg. Volume: 75,202
• 30 Day Avg. Volume: 47,512
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -12.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $25.33
• Price Target Upside: 94.70% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Benitec Biopharma's stock score reflects the company's financial instability and challenges in revenue generation, balanced by positive technical indicators and significant potential in its BB-301 study results. While the stock shows strong market momentum, the overbought conditions and negative valuation metrics suggest caution. The positive corporate event has bolstered the company's prospects, but sustained improvement in financial performance is needed to enhance long-term attractiveness.

Positive Factors

Clinical Trials

BB-301 low-dose regimen continues to demonstrate promise, with increasing durability of response at latest update.

Regulatory Approval

Analysts see a straightforward path to an approvable profile for BB-301 in oculopharyngeal muscular dystrophy, where current treatment options are limited and invasive.

Safety Profile

No severe adverse events have been reported in any study subjects, suggesting a strong safety record for BB-301.

Negative Factors

Data Robustness

The small number of patients in the trial limits the robustness of the data, and further evidence is needed to confirm a dose-response relationship.

Earnings

Benitec Biopharma recorded a net loss of $0.33 per share vs. a forecast of a net loss of $0.27 per share.

Financial Performance

Research and Development expenses were higher than both the analyst's and consensus estimates.

Benitec Biopharma Business Overview & Revenue Model

Company Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

How the Company Makes Money

Benitec Biopharma primarily generates revenue through research and development collaborations, licensing agreements, and partnerships with other pharmaceutical and biotechnology companies. These collaborations often involve upfront payments, milestone payments, and royalties on future product sales. The company's ddRNAi technology platform is licensed to various partners, who utilize it for developing their own therapeutic products. Additionally, Benitec seeks funding through grants and government support for research initiatives, which contributes to its revenue streams.

Benitec Biopharma Financial Statement Overview

Summary

Benitec Biopharma shows financial instability with significant losses and negative cash flow. The income statement reveals declining revenue, significant net losses, and negative margins. The balance sheet is strong with a high equity ratio and low leverage, but ongoing net losses reflected in the negative return on equity are concerning. Despite a robust cash position, the cash flow statement highlights negative operating and free cash flow, indicating high cash burn without substantial revenue improvement.

Income Statement

The income statement shows a declining revenue trend with a significant net loss and negative margins. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of -2916.67%, a net profit margin of -356916.67%, and an EBIT margin of -401550%. Revenue growth is inconsistent, showing a decline compared to previous periods, reflecting challenges in generating sales.

Balance Sheet

Benitec Biopharma's balance sheet shows a strong equity position with an equity ratio of 96.11% in TTM. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage. The return on equity is negative, reflecting ongoing net losses. The company maintains a robust cash position, providing some stability.

Cash Flow

The cash flow statement highlights negative operating cash flow and free cash flow in TTM. The free cash flow growth rate is negative, indicating cash burn. However, the company raised substantial financing, improving liquidity. The operating cash flow to net income ratio is close to 1, suggesting cash flow issues align with net losses.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
6.00K	216.00K	75.00K	73.00K	59.00K	97.00K
	Gross Profit
-175.00K	108.00K	-306.00K	64.00K	-64.00K	-171.06K
	EBIT
-24.09M	-22.49M	-19.08M	-17.85M	-13.60M	-8.28M
	EBITDA
-23.94M	-22.49M	-18.70M	-17.85M	-13.60M	-7.91M
	Net Income Common Stockholders
-21.41M	-21.75M	-19.56M	-18.56M	-13.78M	-8.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.63M	50.87M	2.48M	4.06M	19.77M	9.80M
	Total Assets
10.06M	52.21M	4.46M	5.97M	21.38M	11.59M
	Total Debt
867.00K	284.00K	559.00K	811.00K	213.00K	405.00K
	Net Debt
-7.76M	-50.58M	-1.92M	-3.25M	-19.56M	-9.40M
	Total Liabilities
2.54M	4.96M	4.26M	3.09M	1.37M	1.35M
	Stockholders Equity
7.52M	47.25M	202.00K	2.88M	20.01M	10.24M
Cash Flow		Free Cash Flow
-22.01M	-19.58M	-18.01M	-15.91M	-13.05M	-7.63M
	Operating Cash Flow
-21.82M	-19.40M	-18.01M	-15.90M	-12.83M	-7.54M
	Investing Cash Flow
-191.42K	-179.00K	-1.00K	-13.00K	-221.00K	-94.00K
	Financing Cash Flow
79.75M	68.03M	16.02M	0.00	22.52M	1.77M

Benitec Biopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Neutral. The current price of 13.01 is below the 20-day moving average (MA) of 14.13, above the 50-day MA of 12.29, and above the 200-day MA of 10.37, indicating a neutral trend. The MACD of 0.49 indicates Positive momentum. The RSI at 45.91 is Neutral, neither overbought nor oversold. The STOCH value of 17.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BNTC.

Benitec Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALNY	59 Neutral	$34.92B	―	-414.62%	―	22.97%	38.54%
BNTC	54 Neutral	$342.39M	―	-46.85%	―	-100.00%	72.73%
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
ARWR	47 Neutral	$1.90B	―	-600.68%	―	-98.62%	-86.21%
BLUE	43 Neutral	$39.74M	―	-295.35%	―	184.12%	31.92%
EDIT	39 Underperform	$103.72M	―	-98.10%	―	-58.64%	-40.05%

Benitec Biopharma Corporate Events

Benitec Biopharma Announces Positive Interim Results for BB-301

On March 19, 2025, Benitec Biopharma announced positive interim results from its BB-301 Phase 1b/2a study, presented at the 2025 Muscular Dystrophy Association Conference. The study showed significant improvements in swallowing function for three subjects with Oculopharyngeal Muscular Dystrophy (OPMD), achieving clinically normal swallowing profiles and reducing dysphagic symptom burdens. These results highlight the potential of BB-301 as a promising treatment for OPMD, a condition with limited therapeutic options, and may enhance Benitec’s position in the gene therapy market.